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To provide material suitable for structural studies of
the nicotinic acetylcholine receptor, we have expressed
and purified the NH2-terminal extracellular domain of
the mouse muscle a subunit. Several constructs were
initially investigated using Xenopus oocytes as a con-
venient small scale expression system. A fusion protein
(a210GPI) consisting of the 210 NH2-terminal amino ac-
ids of the a subunit and a glycosylphosphatidylinositol
anchorage sequence conferred surface a-bungarotoxin
binding in oocytes. Coexpression of a210GPI with an
analogous construct made from the d subunit showed no
evidence of heterodimer formation. The a210GPI pro-
tein was chosen for large scale expression in transfected
Chinese hamster ovary cells. The a210GPI protein was
cleaved from these cells and purified on an immunoaf-
finity column. Gel and column chromatography show
that the purified protein is processed as expected and
exists as a monomer. The purified protein also retains
the two distinct, conformation-specific binding sites ex-
pected for the correctly folded a subunit. Circular di-
chroism studies of a210GPI suggest that this region of
the receptor includes considerable b-sheet secondary
structure, with a small proportion of a-helix.
The nicotinic acetylcholine receptor (AChR)1 is the best stud-
ied member of a large class of structurally related neurotrans-
mitter-gated ion channels (1). This class includes both cation
channels (acetylcholine and serotonin type 3 receptors) and
anion channels (glycine, g-aminobutyric acid type A, and an
invertebrate glutamate receptor). Available data for some of
these receptors suggest that each is a pentamer of homologous
or identical subunits. Each subunit contains an NH2-terminal
extracellular domain (;200 residues) followed by four putative
membrane-spanning domains. The regions between the second
and third transmembrane domains (;15 residues) and after
the fourth transmembrane domain (;9 residues) are also
thought to be extracellular but do not appear to be critical for
the folding of the large NH2-terminal domain (see below). The
high degree of sequence similarity among these subunits, es-
pecially in their extracellular domains, suggests that if the
structure of any one was known, molecular modeling could be
used to approximate the structures of the others.
Although there has recently been progress in obtaining
structures of membrane proteins (particularly of bacterial
membrane proteins) (2), many years of effort with Torpedo
AChR have failed to yield crystals that diffract to high resolu-
tion. The highest resolution structural information on these
receptors thus far is that obtained by Unwin (3, 4). Two-dimen-
sional close-packed arrays of AChR in tubular membranes
were prepared from the electric organ of Torpedo marmorata, a
particularly rich source of muscle-type AChR, and examined
using electron microscopy. From these studies a three-dimen-
sional structure to 9 Å resolution (3) and a projection structure
to 7.5 Å (4) were obtained. Although these data provide evi-
dence for the presence of certain elements of secondary struc-
ture, obtaining atomic resolution structural information re-
mains an important goal.
One approach that has been used successfully to obtain
atomic resolution structures of membrane-bound receptors is to
express these proteins heterologously in truncated, soluble
forms. Because these fragments no longer contain long
stretches of hydrophobic amino acids requiring detergent for
solubilization, they crystallize more readily. The structures of
the ligand binding domains of the human growth hormone
receptor (5), the neonatal Fc receptor (6), and the T-cell recep-
tor (7, 8) among others, have been determined in this way.
Although only about half the mass of AChR is extracellular,
several recent studies suggest that the NH2-terminal domain of
a single subunit might be suited to this approach because the a
subunit and various truncated forms of this subunit can fold
independently of the other subunits. The assembly of the
mouse muscle AChR has been studied extensively (9, 10). Each
subunit is synthesized as a preprotein with an NH2-terminal
signal peptide directing translocation into the endoplasmic re-
ticulum. Here the signal peptides are cleaved, and the subunits
fold, become glycosylated, and are assembled into the final
pentameric receptor. The a subunit acquires two conformation-
dependent binding sites during the folding process but before
assembly with the other subunits (11). One of these sites is the
main immunogenic region, which is the epitope recognized by
most experimentally derived antibodies and by a large fraction
of the anti-AChR antibodies from patients with myasthenia
gravis (12). The other binding site, which overlaps with the
ligand binding site, is for the snake venom protein a-bungaro-
toxin (a-Btx). These binding sites are acquired simultaneously
about 20 min after the a subunit is translated. After folding (or
at least partial folding), subunit assembly occurs. Folded a
subunits associate with either d or g subunits to form het-
erodimers. In studies of cells transfected with various combi-
nations of subunits, it has been found that the ad and ag
heterodimers have high affinity cholinergic ligand binding sites
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and that the distinct agonist/antagonist profiles of these two
heterodimers match those of the whole receptor (13).
Several studies have examined the effects of coexpression of
truncated subunits with full-length subunits. Generally, sub-
units truncated after the first transmembrane domain (M1)
have a dominant negative effect on the appearance of receptor
on the plasma membrane, measured either electrophysiologi-
cally or by a-Btx binding (14, 15). The origin of this effect is the
formation of a specific complex between full-length subunits
and the truncated forms. These complexes neither form com-
plete receptors nor undergo transport to the plasma mem-
brane. These results indicate that the NH2-terminal domains of
AChR subunits contain regions that specifically recognize
other subunits. Together with the observation that the a sub-
unit is able to fold independently of the other subunits, these
data suggest that the a subunit NH2-terminal domain may be
a viable target for structural investigation.
In the present experiments, we sought to produce the extra-
cellular domains of AChR subunits in their native states in
quantities sufficient for biochemical and structural studies.
First with Xenopus oocytes and then with Chinese hamster
ovary (CHO) cells, we expressed the truncated NH2-terminal
fragment of the a subunit fused with a sequence directing
membrane anchorage via a glycosylphosphatidylinositol (GPI)
linkage (16). By cleaving this protein from the membrane, we
were able to obtain this portion of the AChR as a soluble
protein. Toxin and antibody binding studies indicate that this
fragment adopts a fold comparable to the corresponding region
of the intact receptor. Circular dichroism (CD) studies reveal
that this fragment of the receptor contains a large proportion of
b-sheet secondary structure.
EXPERIMENTAL PROCEDURES
Reagents—Methionine sulfoximine was from Sigma, and peptide: N-
glycosidase F was obtained from New England Biolabs. Phosphatidyl-
inositol-specific phospholipase C from Bacillus cereus was expressed in
Escherichia coli and purified by isolating periplasmic proteins by os-
motic shock followed by ion exchange chromatography (17). Monoclonal
antibody (mAb) 35 was purified from the supernatant of cultures of
hybridoma cells (American Type Culture Collection, TIB 175) by am-
monium sulfate precipitation. An immunoaffinity column was prepared
by coupling mAb 35 to CNBr-activated Sepharose (Pharmacia Biotech
Inc.) according to the manufacturer’s instructions. mAb 210 was the gift
of Jon Lindstrom (University of Pennsylvania). All other chemicals
were reagent grade.
Construction of GPI-linked Forms—Molecular cloning experiments
were performed by standard methods (18). Full-length cDNAs coding
for the a and d subunits of the mouse muscle AChR in pAMV-PA have
been described (19). The chick a7 subunit was obtained from M. Ballivet
(University of Geneva) and transferred to plasmid pAMV-PA. Site-
directed mutagenesis was used to create unique restriction sites pre-
ceding transmembrane domain 1, and an insert containing the GPI
anchor signal from human placental alkaline phosphatase (20) was
ligated to give a vector encoding the fusion protein. The three constructs
we made were a210GPI, d226GPI, and a7-208GPI (where the numbers
refer to the last amino acid included in the truncated subunit as num-
bered from the first amino acid of the mature protein). These vectors
were linearized with NotI, and mRNA was transcribed using the T7
polymerase mMessage mMachine kit from Ambion (Austin, TX). For
mammalian expression, the coding region for a210GPI was subcloned
into the vector pBJ5.GS (21). This vector contains a strong simian virus
40/human T-lymphotropic virus type1 hybrid promoter for constitutive
expression and the glutamine synthetase minigene (obtained from Cell-
tech, Berkshire, U. K.), which can be used as a selectable marker and
means of gene amplification (22). This marker allows transfected cells
to grow in glutamine-free medium in the presence of methionine sul-
foximine, an inhibitor of the cell’s native glutamine synthetase.
Oocyte Preparation and Injection—Oocytes were removed from Xe-
nopus laevis as described previously (23) and maintained at 18 °C in a
standard solution (ND-96) consisting of 96 mM NaCl, 2 mM KCl, 1 mM
MgCl2, 1.8 mM CaCl2, and 5 mM Hepes supplemented with 2.5 mM
sodium pyruvate, 50 mg/ml gentamicin, and 0.6 mM theophylline, pH
7.5. Oocytes were microinjected (50 nl) with mRNA in three groups:
a210GPI (25 ng of mRNA), a210GPI (12.5 ng) plus d226GPI (25 ng), and
a7-208GPI (25 ng).
Surface expression of a-Btx binding sites was determined by incu-
bating intact oocytes (60 h postinjection) for 2 h at room temperature
with 0.66 nM 125I-a-Btx (2000 Ci/mmol; Amersham Corp.) in ND-96
with 1 mg/ml bovine serum albumin. To assay for antagonist-displace-
able a-Btx binding, oocytes were incubated with a-Btx in the presence
of 200 mM d-tubocurarine chloride. Because a-Btx binds nearly irrevers-
ibly, this experiment measures the reduction in initial rate of a-Btx
binding.
Cell Culture and Transfection—CHO K1 cells were grown in a min-
imum essential medium (Irvine Scientific) supplemented with 5% fetal
bovine serum, 2 mM glutamine, and 100 units/ml penicillin/streptomy-
cin. Stably transfected cell lines were made as described previously (24).
In brief, the pBJ5.GS.a210GPI expression vector was transfected into
CHO cells by a liposome (LipofectAmine)-mediated method (Life Tech-
nologies, Inc.). Two days after transfection the cells were placed in a
minimum essential medium with 5% dialyzed fetal bovine serum with-
out glutamine and with 25 mM methionine sulfoximine. Individual
clones were isolated, and the expression level was determined by 125I-
a-Btx binding and by flow cytometry. Attempts to improve expression
levels by amplification of the glutamine synthetase gene with higher
methionine sulfoximine concentrations were unsuccessful. The highest
expressing cell line was grown in 10-cm plates and in a Cell Pharm
hollow-fiber bioreactor device (Unisyn Fibertec, San Diego).
Flow Cytometric Analysis—Cells released from plates using versene
were incubated with a solution of mAb 210, washed, and then treated
with a fluorescein-conjugated goat F(ab)92 anti-rat IgG (Life Technolo-
gies, Inc.). Flow cytometric analyses were carried out on a Coulter Epics
Elite flow cytometer/cell sorter.
Purification of a210GPI—To release a210GPI from the cell surface,
purified phosphatidylinositol-specific phospholipase C (50 mg) was in-
jected in the cell compartment of the bioreactor or added to dishes
containing the transfected CHO cells. After 2 h, the cell medium (250
ml) was collected and filtered. This solution was passed over the mAb 35
affinity column at a flow rate of 50 ml/h at 4 °C, and the column was
washed with 50 ml of phosphate-buffered saline. Elution of a210GPI
from the column was accomplished with 10 ml of a low pH solution (50
mM sodium citrate, pH 3.0, 1 M NaCl). The eluant was collected into 1
M Tris, pH 8.0 (3 ml), and concentrated to approximately 0.2 mg/ml by
ultrafiltration using an Amicon Centriplus-10 (Mr cutoff of 10,000). The
concentrated protein solution (0.2–0.5 ml) was applied to a fast protein
liquid chromatography Superdex 75 column equilibrated with Tris-
buffered saline or with 5 mM sodium phosphate buffer. This column was
run at room temperature with a flow rate of 0.1 ml/min. The fraction
containing the a210GPI protein was again concentrated with an Ami-
con Centriplus-10.
The a-Btx binding activity of purified, soluble a210GPI was meas-
ured by immobilization of this protein on mAb 35-agarose beads fol-
lowed by binding of 125I-a-Btx. A solution containing 10–100 ng of
a210GPI was added to a suspension of 15 ml of mAb 35-agarose beads
in a 1.5-ml microcentrifuge tube. After 30 min of incubation, the sus-
pension was centrifuged at 2,500 rpm. The supernatant was removed
and replaced with a solution of unlabeled a-Btx and 125I-a-Btx of known
specific activity in phosphate-buffered saline with 1 mg/ml bovine se-
rum albumin. After a 2-h incubation, the beads were again centrifuged
and then washed three times with 1 ml of phosphate-buffered saline by
repeated resuspension and centrifugation. The bound 125I-a-Btx was
measured using a g counter. All incubations were at room temperature
with agitation.
NH2-terminal Amino Acid Sequencing—Protein eluted from the mAb
35 affinity column was electrophoresed on a 10% SDS-polyacrylamide
gel and electroblotted in a Bio-Rad Trans-Blot system onto a polyvinyli-
dene difluoride membrane. The major band visible by Coomassie stain-
ing was cut out and analyzed by an Applied Biosystems model 476A
sequencer.
Circular Dichroism—Spectra were collected using an AVIV CD spec-
trometer model 62A DS. Protein concentration was determined by UV
absorbance at 280 nm, taking into account the amino acid content of
a210GPI and light scattering (25). Cuvettes with path lengths of 0.1 or
1.0 cm were used, and the mean residue ellipticity (degreeszcm2/dmol)
was determined using a mean residue weight of 116. Spectra were
recorded at 20 °C from 250 to 185 nm and were determined as the
average of five scans. Two methods were used to estimate secondary
structure content: (i) the relationship between the mean residue ellip-
ticity at 208 nm and the a-helical content given by Greenfield and
Fasman (26) and (ii) the CONTIN program (27), which fits the spectrum
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between 240 nm and 190 nm, using the protein standards suggested by
Sreerama and Woody (28).
RESULTS
Expression in Oocytes—We made three constructs containing
truncated subunit fragments fused to the human placental
alkaline phosphatase GPI anchorage sequence: a210GPI,
d226GPI, and a7-208GPI. Fig. 1 shows the sequences of the
constructs we tested. In addition to the fusion proteins made
from the extensively studied muscle AChR, we chose to make a
fusion protein with the neuronal a7 subunit because it forms
functional homomeric receptors when expressed heterologously
(29). Thus, one or more a7 subunits are able to form ligand
binding sites without the presence of other types of subunits.
These constructs were studied by microinjection of mRNA
into Xenopus oocytes followed by a-Btx binding. Preliminary
experiments indicated that expression of either a210GPI or
a7-208GPI led to the appearance of a-Btx binding sites on the
oocyte surfaces. As expected for proteins attached to the
plasma membrane by GPI anchors, these a-Btx binding sites
could be cleaved selectively from the cell surface by treatment
with phosphatidylinositol-specific phospholipase C (data not
shown). We next examined whether coexpression of a210GPI
and d226GPI, or the expression of a7-208GPI alone, would lead
to the formation of a high affinity ligand binding site, detecta-
ble as antagonist-inhibitable a-Btx binding. The results of the
a-Btx binding experiment are shown in Fig. 2. Neither expres-
sion of a210GPI alone, nor coexpression of a210GPI and
d226GPI, led to development of a ligand binding site, as evi-
denced by the failure of the nicotinic antagonist d-tubocurarine
to prevent a-Btx binding. In contrast, a7 expressed alone
showed antagonist inhibition of a-Btx binding.
Expression in Mammalian Cells and Purification—Because
the a210GPI protein expressed relatively well in oocytes and
could be cleaved from the surface, we wished to obtain greater
quantities of this protein for further characterization. To scale
up the production of the a210GPI protein, we expressed this
protein in stably transfected mammalian cells. Cell lines were
made using the glutamine synthetase-based expression system
(22). After selection and cloning of high expressing cell lines, we
were able to produce the protein on a 10–100-mg scale. This
modest expression level may reflect the limited surface area
available for GPI-linked proteins or may be the result of the
previously observed inefficient folding of the a subunit (11).
Flow cytometric analysis (Fig. 3A) demonstrates that a210GPI
is expressed on the surface of transfected cells and shows that
the majority of cells have uniform (6 35%) levels of protein/cell.
The most common method of purifying AChR employs bind-
ing to a snake toxin affinity column followed by elution with a
nicotinic agonist. Because the a210GPI protein lacks an ago-
nist site and the toxin-a subunit binding is nearly irreversible,
we sought an alternative purification strategy. We developed
an immunoaffinity-based purification protocol similar to that
used for isolation of a (non-a-Btx binding) chick neuronal AChR
(30). After phosphatidylinositol-specific phospholipase C cleav-
age from cells grown in dishes or the bioreactor, the a210GPI
protein was purified from the serum-containing medium on a
mAb 35 immunoaffinity column. Low pH elution resulted in the
separation of a210GPI from almost all contaminating serum
proteins. Gel filtration chromatography was then performed to
isolate (monomeric) a210GPI from larger molecular weight
proteins (including aggregated a210GPI). This protocol allowed
us to obtain the protein in a nearly pure state, suitable for
various biochemical studies. The specific a-Btx binding of the
purified material rebound to mAb 35-agarose beads was about
16 nmol/mg, which was about 40% of the value calculated on
the basis of protein mass.
Like the native receptor a subunit, the a210GPI protein is
glycosylated. Fig. 3B shows the change in apparent molecular
mass on an SDS-polyacrylamide gel when the purified material
is enzymatically deglycosylated by peptide:N-glycosidase F. A
sample of the a210GPI protein was subjected to protein micro-
sequencing (data not shown). The sequence obtained, SE-
HETRLVAKLF, exactly matches the NH2-terminal 12 residues
of the mature a subunit, verifying that the NH2-terminal signal
peptide had been processed correctly. When bound to mAb
35-agarose beads, the purified material binds a-Btx with a Kd
estimated by Scatchard analysis of about 3 nM (data not
shown), which falls within the range of values reported for the
native receptor (12). The properties of the a210GPI protein
were examined by gel filtration. As shown in Fig. 4, the protein
behaves as a monomer. The apparent molecular mass of the
complex of a210GPI with a-Btx (an 8-kDa protein) was approx-
imately 10 kDa larger, as expected for a one-to-one complex. An
additional gel filtration experiment with 125I-a-Btx demon-
strated that the radioactive label does elute at the ;45-kDa
peak (data not shown).
Circular Dichroism Studies—We used CD to probe the sec-
ondary structure of the expressed extracellular domain. The
CD spectrum of a given protein can be approximated as the
FIG. 2. Surface a-Btx binding by oocytes injected with GPI-
linked constructs. Pools of oocytes were incubated with 0.66 nM
125I-a-Btx either in the absence or presence (1dTc) of 200 mM
d-tubocurarine.
FIG. 1. Constructs used in these ex-
periments. Bold residue indicates point
of truncation and fusion to the human
placental alkaline phosphatase (HPAP)
sequence. Residues in italics have been
removed by truncation or, in the case of
the human placental alkaline phospha-
tase sequence, are removed from the ex-
pressed protein when the GPI anchor is
attached.
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sum of characteristic contributions from different elements of
secondary structure (26). Fig. 5A shows the CD spectrum of
a210GPI compared with the published CD spectrum of the
complete AChR (a2bgd; Fig. 5B) (31). The strong negative el-
lipticities seen around 208 nm and 220 nm for the whole AChR
indicate considerable a-helical content. The CD spectrum of
a210GPI does not show this strong a-helical signature but
instead shows the characteristics of a spectrum of a protein
composed of largely b-sheet structure.
We compared the predicted secondary structure content of
a210GPI with that of whole AChR using two methods of CD
spectral analysis. The method of Greenfield and Fasman (26)
estimates that a210GPI contains 14% a-helix compared with
48% for whole AChR. Analysis using the CONTIN program (27)
suggests that a210GPI contains 12% a-helix, 51% b-sheet, 18%
b-turn, and 20% irregular structure. For the spectrum of whole
AChR, this method estimates 48% a-helix, 26% b-sheet, 13%
b-turn, and 12% irregular structure. The estimates of the a-
helical content of whole AChR exceed that calculated by Mielke
and Wallace, who reported 22–29% a-helix, but others have
noted that their estimate appears to be low based on the re-
ported spectrum (32). In a review of the results of several
spectroscopic methods, it has been suggested that complete
AChR has close to 40% a-helix (33).
The thermal denaturation behavior of a210GPI was also
investigated. When the protein was heated, a small but repro-
ducible change in the CD spectrum was observed. Fig. 6 shows
the spectra of a210GPI before, during, and after heating. Sur-
prisingly, we do not observe a complete melting of the second-
ary structure of the protein. Because the spectra before and
after melting differ, an irreversible change occurs. The most
prominent change in the spectrum occurred in the region
around 230 nm. Fig. 7 shows the change in ellipticity at 231 nm
FIG. 3. Expression of a210GPI in CHO cells. Panel A, flow cyto-
metric analysis of the a210GPI expressed on CHO cells. Staining of
transfected cells by mAb 210; secondary antibody is fluorescein-labeled
goat F(ab9)2 anti-rat IgG. Solid trace, transfected cell line expressing
a210GPI; dotted trace, untransfected CHO cells. Panel B, Coomassie-
stained 12% SDS-polyacrylamide gel electrophoresis of purified
a210GPI, showing the effect of deglycosylation by peptide:N-glycosi-
dase F. Peptide:N-glycosidase F appears as the new band ;34 kDa.
FIG. 4. The extracellular domain of the AChR a subunit exists
as a monomer competent to bind a-bungarotoxin, as demon-
strated by gel filtration chromatography. Gel filtration profiles
(fast protein liquid chromatography Superdex 75 column in 5 mM so-
dium phosphate buffer, pH 7.5, flow rate 0.1 ml/min) of three samples:
purified a210GPI, a mixture of a210GPI with a-Btx (1:2 mol ratio), and
thermally denatured a210GPI. Traces have been scaled by factors of
1.0, 2.6, and 2.3, respectively, to yield equal peak amplitudes. Samples
containing 10–20 mg of a210GPI/run were passed through a 0.2-mm
filter immediately before injection onto the column.
FIG. 5. Panel A, far UV CD spectrum of a210GPI. Panel B, far UV CD
spectrum of whole AChR. Reprinted from Ref. 31 with permission.
CD Studies of the AChR a Subunit Extracellular Domain 25471
as the protein was heated from 24 to 56 °C. After thermal
denaturation, the a210GPI protein no longer behaved as a
monomer on gel filtration (Fig. 4). Separate experiments (not
shown) indicate that the protein also becomes inactive in the
a-Btx/mAb 35 assay when heated in this temperature range.
DISCUSSION
The a210GPI protein expresses well in oocytes and leads to
the accumulation of surface a-Btx binding sites. Encouraged by
this, we expressed and purified this protein on a larger scale
using CHO cells. We are confident that the molecule we have
purified, a210GPI, is folded correctly for the following reasons:
(i) the material was affinity purified using a conformation-
specific antibody; (ii) both the main immunogenic region
epitope and the a-Btx binding site were present in the purified
material; (iii) gel filtration results demonstrate that a210GPI
behaves as a monomer and that it forms a complex with a-Btx
with a slightly greater apparent molecular weight; and (iv) the
a-Btx/mAb 35 binding activity of a210GPI is eliminated by
thermal denaturation.
If about 15% of a210GPI is in an a-helical conformation, this
represents approximately 33 amino acids. The sum of the
lengths of these helices would be roughly 50 Å. In the 9 Å
resolution electron microscopy structure, the extracellular por-
tion of AChR contained three resolvable rods per subunit, ap-
proximately in the middle of that portion of the receptor (3).
These rods in the electron density map appear to extend over at
least 12 Å each. We thus consider our data to be compatible
with the three a-helices identified in the extracellular domain
of AChR. Our data also suggest that there is little or no a-
helical structure elsewhere in the NH2-terminal domain of
AChR, implying that the remainder of the structure may be
composed largely of b-sheet. This is in agreement with an early
amphipathic analysis of AChR sequences which predicted the
extracellular domain of AChR to contain extensive b-sheet
structure (34).
When one considers the constraints that our data may place
on the structure of AChR, an important issue is whether the
secondary structures of the extracellular domains of the other
subunits are largely the same as that for the a subunit. The
high degree of sequence similarly (35–40% identity) and the
results from electron microscopy studies suggest that such an
assumption is reasonable, although there is little direct exper-
imental evidence to address this question. With this caveat, our
data suggest that the nonextracellular portion of AChR must
have a relatively large proportion of a-helical structure if one is
to reconcile these results with the previous CD spectrum of the
entire receptor. Unfortunately, without knowledge of the sec-
ondary structure of the intracellular domain, no conclusions
with respect to the structure of the transmembrane domains
can be made.
The most prominent change in the CD spectrum which oc-
curs upon heating is the appearance of negative ellipticity
around 230 nm. The relatively flat spectrum from 230–240 nm,
a region that should have negative ellipticity because of the
b-sheet signal, suggests that there is an element of structure
giving a positive ellipticity in this region. A positive component
in this region is a feature of aromatic and/or disulfide chro-
mophores, which can acquire rotational strength around 230
nm when they are in specific chiral environments in proteins
(35). Notably, a210GPI is unusually rich in aromatic amino
acids; it has 10 tyrosines and 8 tryptophans, about twice the
expected number based on the average amino acid content of
soluble proteins.
The apparent robustness of the a210GPI secondary structure
to thermal denaturation is not unprecedented. For example,
when bovine b-lactoglobulin A, a b-sheet-rich protein, is ther-
mally denatured, the effect on the secondary structure (as
measured by CD) is very small (36). It has been proposed that
the aggregation/misfolding of many proteins is associated with
the formation of intermolecular b-sheet structures (36, 37). The
relatively low temperature required to cause loss of binding
activity of a210GPI and the inefficient folding of the a subunit
in vivo (with most of the newly synthesized a subunit appear-
ing as non-a-Btx-binding aggregates) suggests that the a sub-
unit is susceptible to this form of misfolding.
We contend that the lower than expected specific binding of
a-Btx by the purified a210GPI is not likely to change substan-
tially our estimates of the secondary structure. We consider the
possible causes for the low specific binding. (i) If the a210GPI
is contaminated with some denatured protein, then the re-
corded CD is a mixture of the folded and unfolded material.
However, the spectrum of the heat-denatured protein is not
markedly dissimilar from that of the correctly folded material.
Therefore, admixture of some fraction of unfolded material will
have little effect on the secondary structure estimates. (ii) If the
protein concentration measurement is too high, this could in-
crease the mean residue ellipticity substantially. Nevertheless,
the shape of the spectrum, which is not very characteristic of
a-helix, would be unchanged. The measurement of protein con-
centration by UV is reported to be accurate within about 10%
(25). (iii) The measured specific binding may be slightly low
because of occlusion of the a-Btx binding site by the antibody
resin or by loss during washing steps.
FIG. 6. CD spectra of a210GPI before, during, and after
heating.
FIG. 7. Temperature dependence of the ellipticity at 231 nm.
Data were obtained by increasing the temperature of the sample in 2 °C
steps, equilibrating for 90 s, and measuring the ellipticity over a period
of 90 s.
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The absence of a ligand binding site on oocytes expressing
only a210GPI agrees with previous studies (11) showing that
although the (complete) a subunit binds a-Btx with high affin-
ity, it lacks the conventional ligand binding site of AChR. This
site forms only when the muscle a subunit is coexpressed with
either the d or g subunit (13). There is no obvious explanation
for the failure of a210GPI and d226GPI to form the ligand
binding site when coexpressed. Coexpression of d226GPI with
a210GPI led to a much lower level of surface expression com-
pared with a210GPI alone, even taking into account the re-
duced amount of a210GPI mRNA injected. Thus expression of
d226GPI may interfere with surface expression of a210GPI by
an unknown mechanism. These findings are very similar to
results reported by Hall and colleagues (38). In contrast, bind-
ing of a-Btx to a7-208GPI was inhibited by d-tubocurarine,
indicating the formation of a ligand binding site and thus
suggesting oligomerization of this protein (extrapolating from
studies on the muscle receptor). Also, it has been reported (39)
that oligomerization of a7 subunits is required for formation of
the a-Btx binding site. It will thus be interesting to express and
characterize a7-208GPI in future experiments.
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